Diagnosis and therapy of alcoholic liver disease

被引:80
作者
Levitsky, J
Mailliard, ME
机构
[1] Univ Nebraska, Coll Med, Div Gastroenterol & Hepatol, Omaha, NE 68583 USA
[2] Univ Nebraska, Ctr Med, Dept Internal Med, Coll Med, Omaha, NE 68583 USA
[3] Vet Affairs Med Ctr, Omaha, NE USA
关键词
liver disease; alcoholic; corticosteroids; tumor necrosis factor-alpha; antibodies; monoclonal;
D O I
10.1055/s-2004-832937
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Alcoholic liver disease (ALD) presents considerable challenges to clinicians. Screening for alcohol abuse and alcoholism should be routine and repeated annually with close attention to signs and symptoms of liver disease. In patients with evidence of liver dysfunction or injury, consideration should be given to performance of liver biopsy for diagnosis and prognosis and prior to initiation of medication with the potential for significant side effects. Therapy depends on the spectrum of pathological liver injury: alcoholic fatty liver, alcoholic hepatitis, and cirrhosis. Abstention is the foundation of therapy for an alcohol problem. Alcoholic fatty liver should improve with abstention, but the similarity to the pathogenesis of nonalcoholic fatty liver and potential for progressive injury merits consideration of lipotropic agents. The continuing mortality, poor acceptance of corticosteroids, and identification of tumor necrosis factor-alpha (TNF-alpha) as an integral component has led to studies of pentoxifylline and, recently, anti-TNF antibody to neutralize cytokines in the therapy of severe alcoholic hepatitis. Antioxidant therapy of alcoholic cirrhosis has significant promise but will require large clinical trials.
引用
收藏
页码:233 / 247
页数:15
相关论文
共 173 条
  • [1] Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711
  • [2] Agelink MW, 1998, ALCOHOL ALCOHOLISM, V33, P164
  • [3] Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial
    Akriviadis, E
    Botla, R
    Briggs, W
    Han, S
    Reynolds, T
    Shakil, O
    [J]. GASTROENTEROLOGY, 2000, 119 (06) : 1637 - 1648
  • [4] ALEXANDER JF, 1971, AM J GASTROENTEROL, V56, P515
  • [5] Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection
    Anderson, S
    Nevins, CL
    Green, LK
    El-Zimaity, H
    Anand, BS
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (07) : 1393 - 1398
  • [6] Andrew Barr Drink, 1999, DRINK SOCIAL HIST AM
  • [7] [Anonymous], 2000, DIAGN STAT MAN MENT
  • [8] Carbohydrate-deficient transferrin as an indicator of drinking status during a treatment outcome study
    Anton, RF
    Moak, DH
    Latham, P
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1996, 20 (05) : 841 - 846
  • [9] Diagnostic characteristics of different carbohydrate-deficient transferrin methods in the detection of problem drinking:: Effects of liver disease and alcohol consumption
    Anttila, P
    Järvi, K
    Latvala, J
    Blake, JE
    Niemelä, O
    [J]. ALCOHOL AND ALCOHOLISM, 2003, 38 (05): : 415 - 420
  • [10] Oxidants and antioxidants in alcohol-induced liver disease
    Arteel, GE
    [J]. GASTROENTEROLOGY, 2003, 124 (03) : 778 - 790